Abstract Library

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers

Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merkel C

Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,

Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,

#2975 Next Generation Sequencing of Pancreatic Neuroendocrine Tumors in Russian Cohort

Introduction: The appearance of next generation sequencing (NGS), - a powerful high-performance method, allowed accumulation of a large amount of information concerning genetic and epigenetic patterns, however, the problem of matching clinical, histological picture with genetic structure in pNETs remains open.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Trifanov V

Authors: Trifanov V, Kit O, Timoshkina N, Gvaldin D, Karnauhov N,

Keywords: Next generation sequencing, pancreatic neuroendocrine tumors,

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#2957 New Evidence of Emerging Nodal Metastasis in Staging System after Surgical pNET Resection as Predictive Factor for Recurrence. Result from Monocentric Retrospective Series

Introduction: New evidence is emerging of the role of pNETs lymphatic metastasis in terms of Oncological Outcomes. A specific staging classification is not actually available.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo l

Authors: Mastrangelo L, Romboli A, Masetti M, Zanello M, Cipressi C,

Keywords: lymph node status, neuroendocrine tumor, pancreas, prognosis, surgery,